Department of Internal Medicine, Ribeirao Preto Medical School, University of São Paulo, São Paulo, SP, Brazil.
Department of Microbiology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, São Paulo, MG, Brazil.
Probiotics Antimicrob Proteins. 2024 Feb;16(1):53-61. doi: 10.1007/s12602-022-10014-w. Epub 2022 Nov 29.
Probiotics should be administered in adequate amounts to confer health benefits. Probiotic dose-response studies are still missing. Saccharomyces cerevisiae UFMG A-905 prevented asthma development; however, the ideal dose has not been investigated. We evaluated the optimal dose and administration regimen of S. cerevisiae UFMG A-905 in the prevention of asthma. Male Balb/c mice were sensitized intraperitoneally with ovalbumin (OVA) and challenged with OVA intranasally. Mice received, via gavage, daily or alternate-day S. cerevisiae UFMG A-905. In daily regimen, different concentrations (10, 10, or 10 CFU/mL) were given 10 days before OVA sensitization and during challenges. In alternate-day regimen, a concentration of 10 CFU/mL was administered three times per week for 5 weeks, starting 2 weeks prior to the first sensitization. After the last challenge, in vivo bronchial hyperresponsiveness and airway and lung inflammation were assessed. OVA-challenged mice, when compared to saline-challenged mice, presented a significant increase in bronchial hyperresponsiveness and airway and lung inflammation. Daily and alternate-day administration of 10 CFU/mL of S. cerevisiae UFMG A-905 significantly reduced bronchial hyperresponsiveness; lower concentrations of S. cerevisiae UFMG A-905 did not significantly reduce bronchial hyperresponsiveness. Daily regimen with the highest concentration significantly reduced total cell number, eosinophil count in the BAL, and the levels of IL-4, IL-5, and IL-13. Daily administration of S. cerevisiae UFMG A-905 at 10 and 10 CFU/mL and alternate-day regimen did not significantly decrease airway and lung inflammation. S. cerevisiae UFMG A-905 led to a significant attenuation of bronchial hyperresponsiveness and lung inflammation in a dose-dependent manner.
益生菌应以足够的量施用以带来健康益处。益生菌剂量反应研究仍然缺失。酿酒酵母 UFMG A-905 可预防哮喘的发生；然而，尚未研究其理想剂量。我们评估了酿酒酵母 UFMG A-905 预防哮喘的最佳剂量和施用方案。雄性 Balb/c 小鼠通过腹膜内注射卵清蛋白（OVA）致敏，并通过鼻内挑战 OVA。通过灌胃给予小鼠每日或隔日接受酿酒酵母 UFMG A-905。在每日方案中，在 OVA 致敏前 10 天和攻毒期间给予不同浓度（10、10 或 10 CFU/mL）。在隔日方案中，每周 3 次给予浓度为 10 CFU/mL 的药物，共 5 周，在首次致敏前 2 周开始。最后一次攻毒后，评估体内支气管高反应性以及气道和肺炎症。与盐水攻毒的小鼠相比，OVA 攻毒的小鼠的支气管高反应性以及气道和肺炎症显著增加。每日和隔日给予 10 CFU/mL 的酿酒酵母 UFMG A-905 可显著降低支气管高反应性；较低浓度的酿酒酵母 UFMG A-905 不能显著降低支气管高反应性。最高浓度的每日方案可显著降低 BAL 中的总细胞数、嗜酸性粒细胞计数以及 IL-4、IL-5 和 IL-13 的水平。每日给予 10 CFU/mL 和隔日给予酿酒酵母 UFMG A-905 均不能显著降低气道和肺炎症。酿酒酵母 UFMG A-905 以剂量依赖的方式显著减轻支气管高反应性和肺炎症。
